Compare MRCY & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRCY | TMDX |
|---|---|---|
| Founded | 1981 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.9B |
| IPO Year | 1998 | 2019 |
| Metric | MRCY | TMDX |
|---|---|---|
| Price | $70.52 | $136.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | $76.43 | ★ $133.00 |
| AVG Volume (30 Days) | 596.2K | ★ 835.5K |
| Earning Date | 11-04-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.70 |
| EPS | N/A | ★ 2.54 |
| Revenue | ★ $932,798,000.00 | $566,354,000.00 |
| Revenue This Year | $6.17 | $38.84 |
| Revenue Next Year | $8.23 | $20.43 |
| P/E Ratio | ★ N/A | $53.83 |
| Revenue Growth | 8.63 | ★ 41.20 |
| 52 Week Low | $37.28 | $55.00 |
| 52 Week High | $85.33 | $156.00 |
| Indicator | MRCY | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 54.31 |
| Support Level | $66.58 | $133.50 |
| Resistance Level | $72.22 | $156.00 |
| Average True Range (ATR) | 2.55 | 8.50 |
| MACD | 0.45 | 0.41 |
| Stochastic Oscillator | 77.02 | 55.98 |
Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.